Insider Selling: Natera, Inc. (NASDAQ:NTRA) COO Sells $428,556.45 in Stock

Natera, Inc. (NASDAQ:NTRA) COO Robert Alan Schueren sold 4,395 shares of the stock in a transaction dated Friday, June 4th. The stock was sold at an average price of $97.51, for a total value of $428,556.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Robert Alan Schueren also recently made the following trade(s):

  • On Tuesday, June 8th, Robert Alan Schueren sold 12,073 shares of Natera stock. The stock was sold at an average price of $105.21, for a total value of $1,270,200.33.
  • On Tuesday, April 13th, Robert Alan Schueren sold 22,093 shares of Natera stock. The stock was sold at an average price of $104.21, for a total value of $2,302,311.53.
  • On Friday, April 9th, Robert Alan Schueren sold 1,912 shares of Natera stock. The stock was sold at an average price of $104.86, for a total value of $200,492.32.
  • On Monday, March 29th, Robert Alan Schueren sold 6,088 shares of Natera stock. The stock was sold at an average price of $83.94, for a total value of $511,026.72.
  • On Wednesday, March 10th, Robert Alan Schueren sold 6,327 shares of Natera stock. The stock was sold at an average price of $97.33, for a total value of $615,806.91.

Natera stock opened at $105.56 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.74 and a quick ratio of 4.60. The company has a market cap of $9.28 billion, a P/E ratio of -34.05 and a beta of 1.32. Natera, Inc. has a one year low of $39.43 and a one year high of $127.19. The stock’s 50 day moving average is $100.17.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, May 6th. The medical research company reported ($0.74) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.31. Natera had a negative return on equity of 59.71% and a negative net margin of 57.47%. The business had revenue of $152.32 million during the quarter, compared to the consensus estimate of $114.42 million. During the same quarter last year, the company earned ($0.45) EPS. Natera’s revenue was up 62.0% on a year-over-year basis. On average, sell-side analysts anticipate that Natera, Inc. will post -3.93 EPS for the current year.

A number of research firms have recently weighed in on NTRA. Piper Sandler raised their price target on Natera from $127.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, February 26th. Morgan Stanley cut their price target on Natera from $140.00 to $135.00 and set an “overweight” rating for the company in a research note on Monday, May 10th. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a report on Thursday, April 29th. Truist Securities lowered their price objective on Natera from $143.00 to $129.00 and set a “buy” rating on the stock in a report on Tuesday, May 25th. Finally, Wells Fargo & Company began coverage on Natera in a report on Tuesday, May 25th. They set an “overweight” rating and a $110.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $116.75.

Institutional investors and hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. bought a new position in Natera in the 1st quarter valued at $28,000. Tobam bought a new position in Natera in the 1st quarter valued at $38,000. Harvest Fund Management Co. Ltd bought a new position in Natera in the 4th quarter valued at $39,000. Benjamin F. Edwards & Company Inc. bought a new position in Natera in the 1st quarter valued at $49,000. Finally, AlphaMark Advisors LLC acquired a new stake in shares of Natera in the 1st quarter valued at $51,000. Hedge funds and other institutional investors own 96.09% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: Do equity income investments outperform growth and income investments?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.